A Randomized Blinded, Placebo-Controlled, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the Investigational eFlow Inline System in Mechanically Ventilated Patients With Gram-negative Bacterial Pneumonia (IASIS)

Trial Profile

A Randomized Blinded, Placebo-Controlled, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the Investigational eFlow Inline System in Mechanically Ventilated Patients With Gram-negative Bacterial Pneumonia (IASIS)

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Amikacin/fosfomycin (Primary)
  • Indications Gram-negative infections; Pneumonia
  • Focus Therapeutic Use
  • Acronyms IASIS
  • Sponsors Cardeas Pharma
  • Most Recent Events

    • 09 May 2016 Status changed from active, no longer recruiting to completed.
    • 11 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 28 Jan 2016 Planned End Date changed from 1 Jan 2016 to 1 Apr 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top